期刊文献+

不同途径尘螨特异性免疫治疗对哮喘患儿早期免疫学指标的影响 被引量:7

The different ways of dust mite specific immunotherapy on the effects of early immunological indexes in children with asthma
原文传递
导出
摘要 目的了解哮喘患儿经不同途径尘螨特异性免疫治疗后早期免疫学指标的动态变化。方法收集尘螨致敏的学龄期哮喘患儿78例,分为皮下免疫治疗组(SCIT组,37例)、舌下免疫治疗组(SLIT组,41例),采用病例自身对照研究。治疗前、治疗6个月和12个月时监测血清屋尘螨特异性IgE(sIgE-d1)、粉尘螨特异性IgE(sIgE-d2)、屋尘螨特异性IgG4(sIgG4-d1)、粉尘螨特异性IgG4(sIgG4-d2)及总IgE(T-IgE)水平变化。结果SCIT组于治疗6个月时sIgG4-d1及sIgG4-d2水平即较治疗前显著升高[0.38(0.08~2.07) KUA/L比1.79(0.25~7.92)KUA/L,0.34(0.15~1.83)KUA/L比1.81(0.16~4.68)KUA/L,P均〈0.05];治疗12个月时较治疗6个月时sIgG4-d2持续升高[1.81(0.16~4.68)KUA/L比2.47(0.32~5.72)KUA/L,P〈0.05],同时sIgE-d1、T-IgE水平显著降低(P均〈0.05);治疗12个月时较治疗前各免疫学指标均有显著改善(P均〈0.05)。SLIT组于治疗6个月时sIgE-d1、sIgE-d2、T-IgE水平均较治疗前显著降低[49.90(1.35~179.50)KUA/L比27.00(0.46~259.50)KUA/L,68.00(1.19~231.60)KUA/L比41.50(0.53~262.80)KUA/L,337.00(5.21~1521.00)KUA/L比209.00(4.95~1374.00)KUA/L,P均〈0.05],sIgG4-d1及sIgG4-d2水平无明显变化;治疗12个月时较治疗6个月时各免疫学指标均无明显变化;治疗12个月时较治疗前sIgE-d1、sIgE-d2、T-IgE水平显著降低[50.10(1.35~179.50)KUA/L比27.30(0.37~205.50)KUA/L,59.50(1.19~231.60)KUA/L比31.40(0.45~200.70)KUA/L,337.00(5.21~1521.00)KUA/L比117.00(3.50~1076.00)KUA/L,P均〈0.05],sIgG4-d1、sIgG4-d2水平无显著变化。结论不同方式的免疫治疗可能通过不同的免疫机制达到治疗效果,SLIT可能不一定通过IgG4的升高达到治疗效果,其潜在机制仍需进一步研究。
出处 《中华实用儿科临床杂志》 CSCD 北大核心 2016年第21期1665-1667,共3页 Chinese Journal of Applied Clinical Pediatrics
  • 相关文献

参考文献14

  • 1谭力,吴澄清,张泉.支气管哮喘患儿血清25-羟维生素D3水平及其与肺功能、呼出气一氧化氮的关系[J].中国小儿急救医学,2016,23(9):613-615. 被引量:25
  • 2Global strategy for asthma management and prevention update 2015[EB/OL]. http://www.ginasthma.org.
  • 3中华医学会儿科学分会呼吸学组.儿童支气管哮喘防治常规(试行)[J].中华儿科杂志,2004,42(2):100-106. 被引量:2631
  • 4BlumbergaG, GroesL, DahlR. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma[J]. Allergy, 2011, 66(2): 178-185.DOI: 10.1111/j.1398-9995.2010.02451.x.
  • 5陈伯亚,龙自铭,黄燕君,曾坚明.舌下含服粉尘螨滴剂治疗单一和多重过敏变应性鼻炎患者的临床疗效评估[J].中华耳鼻咽喉头颈外科杂志,2013,48(7):549-554. 被引量:47
  • 6PleskovicN, BartholowA, SkonerDP.Sublingual immunotherapy in children: the recent experiences[J]. Curr Opin Allergy Clin Immunol, 2014, 14(6): 582-590.DOI: 10.1097/ACI.0000000000000112.
  • 7JutelM, AgacheI, BoniniS, et al.International consensus on allergy immunotherapy[J]. J Allergy Clin Immunol, 2015, 136(3): 556-568.DOI: 10.1016/j.jaci.2015.04.047.
  • 8MosbechH, DeckelmannR, de BlayF, et al.Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial[J]. J Allergy Clin Immunol, 2014, 134(3): 568-575.e7.DOI: 10.1016/j.jaci.2014.03.019.
  • 9MarognaM, BraidiC, BrunoME, et al.The contribution of sublingual immunotherapy to the achievement of control in birch-related mild persistent asthma: a real-life randomised trial[J]. Allergol Immunopathol (Madr), 2013, 41(4): 216-224.DOI: 10.1016/j.aller.2012.07.004.
  • 10JutelM, van de VeenW, AgacheI, et al.Mechanisms of allergen-speci-fic immunotherapy and novel ways for vaccine development[J]. Allergol Int, 2013, 62(4): 425-433.DOI: 10.2332/allergolint.13-RAI-0608.

二级参考文献35

  • 1顾之燕,董震.变应性鼻炎的诊治原则和推荐方案(2004年,兰州)[J].中华耳鼻咽喉头颈外科杂志,2005,40(3):166-167. 被引量:1713
  • 2孙劲旅,陈军,张宏誉.尘螨过敏原的交叉反应性[J].昆虫学报,2006,49(4):695-699. 被引量:21
  • 3中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组.变应性鼻炎免疫治疗专家共识.中华耳鼻咽喉头颈外科杂志,2011,46:976-980.
  • 4WHO Position Paper.Allergen immunotherapy:therapeuticvaccines for allergic diseases.Geneva:January 27-29 1997.Allergy,1998,53(44 Suppl):142.
  • 5Paul CP.Update on sublingual immunotherapy.Ann AllergyAsthmalmmunol,2006 ’ 96(2 Suppl 1):S22-25.
  • 6Valovirta E,Myrseth SE,Palkonen S.The voice of the patients:allergic rhinitis is not a trivial disease.Curr Opin Allergy ClinImmunol,2008,8(1):1-9.
  • 7Canonica GW,Bousquet J,Casale T,et al.Sub-lingualimmunotherapy:World Allergy Organization Position Paper 2009.Allergy,2009,64 Suppl 91:1-59.
  • 8Li J,Sun B,Huang Y,et al.A multicentre study assessing theprevalence of sensitizations in patients with asthma and/or rhinitisin China.Allergy,2009,64(7):1083-1092.
  • 9Lind P,Hansen OC,Horn N.The binding of mouse hybridomaand human IgE antibodies to the major fecal allergen,Der p I,ofDermatophagoides pteronyssinus.Relative binding site locationand species specificity studied by solid-phase inhibition assayswith radiolabeled antigen.J Immunol,1988,140(12):4256-4262.
  • 10Thomas WR,Smith WA,Hales BJ,et al.Characterization andimmunobiology of house dust mite allergens.Int Arch AllerygImmunol,2002,129(1):1-18.

共引文献2700

同被引文献68

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部